KADCYLA is a prescription medicine used to treat HER2+ breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
Talk to your healthcare team about the potential benefits and risks of KADCYLA.
Because everyone is different, no one can say for sure if KADCYLA will work for you, or for how long it will keep working.
In a clinical study, people who took KADCYLA lived without their cancer growing and spreading for longer (9.6 months), on average, than people who took the combination of Tykerb and Xeloda (6.4 months)
KADCYLA can cause serious side effects including severe liver problems and heart problems. Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects.
Other possible serious side effects of KADCYLA include:
See additional information on these side effects below or talk to your doctor.
Less than 6% of people who took KADCYLA or lapatinib and capecitabine lost their hair (3.9% in the KADCYLA arm and 5.1% in the lapatinib and capecitabine arm)
*Tykerb is a registered trademark of GlaxoSmithKline.
Understand how KADCYLA is given for metastatic breast cancer.
If you need help paying for KADCYLA, there may be options to help.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.